A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin
Comparison in people · 2008
- What was studied
- Clinical population; enrollment and allocation not verified
- What the source reports
- This clinical publication compared Noopept and piracetam for cognitive impairment after vascular or traumatic brain disease. The indexed citation supplies no arm sizes or cognitive scores.
Study data at a glance
- Participants or experimental model
- Clinical population; enrollment and allocation not verified
- Reported results
- This clinical publication compared Noopept and piracetam for cognitive impairment after vascular or traumatic brain disease. The indexed citation supplies no arm sizes or cognitive scores.
Study limitations and source details
Study limitations
- No effect size, participant count or safety conclusion is inferred from the title.
- The 2008/2009 comparison and related EEG report may overlap; not counted as independent replication.
Related publications may describe some of the same participants or experiments.
Source details
Indexed citation
Indexed citation checked; complete article not recovered. Study type is based on the database record and abstract, where available.
Metadata only
Sources checked
Citation
Neznamov GG, Teleshova ES. A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Related compounds
Noopept
Omberacetam (GVS-111), a synthetic derivative of the Pro–Gly dipeptide. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester. Studies examined cognition and the metabolite cycloprolylglycine.
Piracetam
A synthetic compound in the racetam family, also known by the brand Nootropil. It appears in neurological research and historical fatigue-related combination studies.